Google
ATYR — ATYR PHARMA, INC. (Healthcare >> Biotechnology)
ATYR FAQ
What is ATYR's ROE?
ATYR PHARMA, INC. reports a Return on Equity (ROE) of -120.88%.
What is ATYR's dividend yield?
ATYR PHARMA, INC. offers a dividend yield of 0.00%.
What is ATYR's Deepscope Quality Score?
Deepscope rates ATYR's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy ATYR?
Deepscope's AI Timing Score for ATYR is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does ATYR belong to?
ATYR PHARMA, INC. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 0.44
Price
-0.03
(-5.94%)
Day Change
|
|
|---|
ATYR, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
ROAがROEに比べて低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 53 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.44 |
| PBV / Sector |
0.80 / 4.75
GREAT
|
| Earning Per Share | -0.67 |
| PE / Sector |
N/A / 17.65
|
| PEG or PE/Growth / Sector |
N/A / 0.52
|
| Average 1M Daily Value |
2.35 M
GREAT
|
| Average 1W Daily Value |
0.93 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
56% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-09 09:40:06 |
| Symbol | ATYR |
| Name | ATYR PHARMA, INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 98.05 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 46.08 / 9,000.42 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 10240 Sorrento Valley Road, San Diego, CA, United States, 92121
Phone: 858 731 8389
Website: https://atyrpharma.com
Employees: 58
Sector: Healthcare >> Biotechnology
Description: aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
